EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for the First-Line Treatment of Advanced Renal Cell Carcinoma in Europe
HEMEL HEMPSTEAD, England, June 23, 2017 -- (Healthcare Sales & Marketing Network) -- EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced that the European Medicines Agency's Committ... Biopharmaceuticals, Oncology, Regulatory EUSA Pharma, FOTIVDA, tivozanib, renal cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 23, 2017 Category: Pharmaceuticals Source Type: news

Considering a Clinical Trial? Phase II Clinical Study of Lenvatinib
Eisai announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.06/17/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 17, 2017 Category: Urology & Nephrology Source Type: news

Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth
The mechanistic target of rapamycin complex 1 (mTORC1) is recruited to the lysosome by Rag guanosine triphosphatases (GTPases) and regulates anabolic pathways in response to nutrients. We found that MiT/TFE transcription factors—master regulators of lysosomal and melanosomal biogenesis and autophagy—control mTORC1 lysosomal recruitment and activity by directly regulating the expression of RagD. In mice, this mechanism mediated adaptation to food availability after starvation and physical exercise and played an important role in cancer growth. Up-regulation of MiT/TFE genes in cells and tissues from patients and...
Source: ScienceNOW - June 15, 2017 Category: Science Authors: Di Malta, C., Siciliano, D., Calcagni, A., Monfregola, J., Punzi, S., Pastore, N., Eastes, A. N., Davis, O., De Cegli, R., Zampelli, A., Di Giovannantonio, L. G., Nusco, E., Platt, N., Guida, A., Ogmundsdottir, M. H., Lanfrancone, L., Perera, R. M., Zoncu Tags: Genetics reports Source Type: news

Epacadostat Plus Pembrolizumab Shows Early Promise in Advanced RCC
Epacadostat plus pembrolizumab yielded “encouraging response outcomes” among patients with 0 or 1 prior lines of therapy for advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: News Renal Cell Carcinoma Source Type: news

16-Gene Recurrence Score for High-Risk RCC Offers Prognostic Value
Analysis from a phase III trial confirmed the prognostic value of a 16-gene recurrence score in patients with high-risk renal cell carcinoma undergoing adjuvant sunitinib therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

Aveo Oncology ’s tivozanib enters Phase II part of TiNivo trial for RCC
US-based biopharmaceutical firm Aveo Oncology ’s oral drug candidate tivozanib has advanced into the Phase II part of the Phase I/II TiNivo clinical trial to treat advanced renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - June 8, 2017 Category: Pharmaceuticals Source Type: news

Pazopanib Not Recommended as Adjuvant Therapy of Locally Advanced RCC
Pazopanib 600 mg daily as adjuvant therapy did not prolong disease-free survival for patients with locally advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

Atezolizumab/Bevacizumab in Metastatic RCC Moves to Phase III Trial
This video reviews second-line data from the IMmotion150 trial, which initially studied atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2017 Category: Cancer & Oncology Authors: Michael B. Atkins, MD Tags: Conferences/ASCO Renal Cell Carcinoma News Videos Genitourinary Cancers Source Type: news

Pembrolizumab Plus Pazopanib Is Not Safe for Patients with RCC
Liver toxicity precludes development of pembrolizumab plus pazopanib immunotherapy for patients with advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

First-Line Avelumab/Axitinib Shows Early Antitumor Activity in mRCC
Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Conferences/ASCO Renal Cell Carcinoma Genitourinary Cancers News Source Type: news

Biomarkers Predict RCC Treatment Outcomes
Plasma levels of HGF, BAP1 and PBRM1 gene mutation status, and angiogenesis gene expression are promising predictive biomarkers for survival in RCC patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

Clinicians Must Tailor Treatment for Metastatic RCC
In this interview we discuss decision making in the treatment of metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2017 Category: Cancer & Oncology Authors: Neeraj Agarwal, MD Tags: Conferences/ASCO Renal Cell Carcinoma Genitourinary Cancers Q & Source Type: news

Individualized Sunitinib Dosing Improves Response, Survival in RCC
Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

X4 Pharmaceuticals begins Phase II trial of X4P-001 to treat ccRCC
US-based biotechnology firm X4 Pharmaceuticals has begun the Phase II portion of its ongoing Phase I/II clinical trial with dosing of X4P-001 in combination with Inlyta (axitinib) in advanced clear cell renal cell carcinoma (ccRCC) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - May 25, 2017 Category: Pharmaceuticals Source Type: news

@FDA_Patient_Net seeks advocates who have experience with renal cell carcinoma. For more information go to http://go.usa.gov/x9hCY   #cancerpic.twitter.com/6l58hzi46E
@FDA_Patient_Net seeks advocates who have experience with renal cell carcinoma. For more information go to http://go.usa.gov/x9hCY  #cancer pic.twitter.com/6l58hzi46E (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - May 25, 2017 Category: Medical Devices Authors: ( at FDA_Patient_Net) Source Type: news

Phase 2 Study Comparing CB-839 With Everolimus vs. Placebo With Everolimus
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)05/25/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 25, 2017 Category: Urology & Nephrology Source Type: news

Phase 2/3 Trial of Abexinostat In Renal Cell Carcinoma
Xynomic Pharma, a clinical stage US oncology drug R&D company, today announced that it has entered into a strategic partnership with the University of California San Francisco ("UCSF") to conduct PAX Study, a multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat versus Pazopanib monotherapy in patients with locally advanced or metastatic renal cell carcinoma ("RCC").05/23/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 23, 2017 Category: Urology & Nephrology Source Type: news

Use of Nephron-Sparing Surgery for Stage I RCC Increasing
The use of nephron-sparing surgery to treat stage I renal tumors increased between 2009 to 2013 in Australia, showing increased compliance with international guidelines. (Source: CancerNetwork)
Source: CancerNetwork - May 4, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Survival Improves in mRCC With Surgical Metastasectomy Survival Improves in mRCC With Surgical Metastasectomy
Patients with metastatic renal cell carcinoma who had complete surgical metastasectomy have better survival outcomes than patients with no resection or incomplete resection of metastases.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 4, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Comprehensive atlas of immune cells in renal cancer
(University of Zurich) Researchers from the University of Zurich have individually analyzed millions of immune cells in tumor samples from patients with renal cell carcinoma. They are now presenting an immunological atlas of the tumor environment for the first time, leading to possible further developments of immunotherapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2017 Category: Cancer & Oncology Source Type: news

SPECT/CT can solve renal cell carcinoma diagnosis conundrum
By turning to a SPECT/CT scan with technetium-99m (Tc-99m) sestamibi, clinicians...Read more on AuntMinnie.comRelated Reading: SPECT/CT advances abdominal emergency diagnoses MRI shows benefits for renal cell carcinoma CEUS shines for indeterminate small renal masses SNMMI: SPECT/CT shines at sentinel lymph-node imaging SPECT/CT aids in tough endocarditis cases (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 27, 2017 Category: Radiology Source Type: news

Advanced RCC Can Still Respond to Nivolumab After Initial Progression
A subset of patients with advanced renal cell carcinoma experienced a reduction in tumor size after undergoing postprogression treatment with nivolumab. (Source: CancerNetwork)
Source: CancerNetwork - April 26, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Mayo research shows surgery adds years for kidney cancer patients
(Mayo Clinic) Mayo Clinic researchers have discovered that surgery could more than double life expectancy for many patients with late-stage kidney cancer, giving them anywhere from two to almost 10 years more than they'd have without the surgery. A paper, published recently in The Journal of Urology, found a 'clinically meaningful difference in survival' between renal cell carcinoma patients who had surgery to completely remove secondary tumor growths, called metastases, compared to those who didn't. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 24, 2017 Category: Cancer & Oncology Source Type: news

Supplement can lessen kidney damage linked to genetic mutations in transgenic fruit flies
(Children's National Health System) An off-the-shelf dietary supplement available for pennies per dose demonstrated the ability to reverse cellular damage linked to specific genetic mutations in transgenic fruit flies, an experimental model of genetic mutation-induced renal cell injury that features striking similarities to humans, a Children's National Health System research team reports April 20 in Journal of the American Society of Nephrology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 20, 2017 Category: Global & Universal Source Type: news

Cancer-Related End-Stage Renal Disease Incidence Increasing
From 1983 to 2007, the incidence of renal-malignancy end-stage renal disease has greatly increased, according to the results of a study published. (Source: CancerNetwork)
Source: CancerNetwork - April 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Cancer Complications Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA ® (pembrolizumab)
Dateline City: WILMINGTON, Del.& KENILWORTH, N.J.Clinical Program Now Includes Seven Registrational Trials Across Five Tumor TypesWILMINGTON, Del.& KENILWORTH, N.J.–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte ’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA® (pembrolizumab), Merck ’s anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung can...
Source: Merck.com - Corporate News - March 31, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news

G-BA confirms additional benefit of Eisai ’s Kisplyx to treat advanced RCC
The German Federal Joint Committee (G-BA) has confirmed the additional benefit of Eisai ’s in-house developed anti-cancer agent, Kisplyx (lenvatinib mesylate), to treat advanced renal-cell carcinoma (RCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 30, 2017 Category: Pharmaceuticals Source Type: news

Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer
(University of Texas M. D. Anderson Cancer Center) Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2017 Category: Global & Universal Source Type: news

Adjuvant TKI Use in High-Risk Clear Cell RCC Not Effective
Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 24, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Make the Diagnosis: Risk-revealing Rash
(MedPage Today) -- Case Findings: A 60-year-old woman presents with a new non-pruritic rash and muscle weakness. She reports difficulty carrying her groceries and getting up from the couch. A physical examination reveals an erythematous rash on her face, back, and neck, and violaceous papules on her eyelids and the joints of her fingers. Laboratory tests reveal positive antinuclear antibodies and an elevated serum creatinine kinase. This condition is associated with an increased risk of malignancy including renal cell carcinoma, leukemia, thyroid cancer, and ovarian cancer. What is your diagnosis? (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 20, 2017 Category: Hematology Source Type: news

"Richness of Choices" Available in Kidney Cancer, But Patient Selection Is Key
Between the frontline and second-line settings, there are multiple treatment options available for patients with renal cell carcinoma (RCC), but it is critically important for oncologists to decide on an agent with a patient ’s characteristics—and goals—in mind, according to Eric Jonasch, MD.03/11/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 10, 2017 Category: Urology & Nephrology Source Type: news

Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1-Positive mRCC
This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 3, 2017 Category: Cancer & Oncology Authors: David F. McDermott, MD Tags: Videos Genitourinary Cancers Source Type: news

Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1 –Positive mRCC
This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 3, 2017 Category: Cancer & Oncology Authors: David F. McDermott, MD Tags: Videos Genitourinary Cancers Source Type: news

Medical News Today: Investigational drug shows promise for hard-to-treat renal cancer
Savolitinib seems to halt tumor progression in some people with papillary renal cell carcinoma - a form of kidney cancer - according to new study results. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 1, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Vorinostat Plus Bevacizumab Had Activity in Previously Treated RCC
Using the HDAC inhibitor vorinostat plus the VEGF inhibitor bevacizumab resulted in clinical activity in patients with clear cell renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 28, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

First Look at Combo With Immunotherapy in Untreated mRCC First Look at Combo With Immunotherapy in Untreated mRCC
The immunotherapy atezolizumab in combination with bevacizumab had some'provocative'phase 2 results in untreated, advanced renal cell carcinoma.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 27, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Your participation in this research project can help ensure that the company ’s brochure and other materials are relevant to patients
A major pharmaceutical manufacturer has commissioned market research to help improve its communications directed toward Renal Cell Carcinoma (RCC) patients.Your participation in this research project can help ensure that the company’s brochure and other materials are relevant to patients’ concerns and expressed in a clear and comprehensible way.Fieldwork, an independent healthcare research and consulting firm located in the U.S., has been engaged to conduct these research interviews on pharmaceutical manufacturer’s behalf. The research project consists of a one-time telephone interview lasting 60 minutes....
Source: Kidney Cancer Association - February 23, 2017 Category: Urology & Nephrology Source Type: news

Argos says independent committee predicts trial failure
Argos Therapeutics Inc said on Wednesday that an independent data monitoring committee concluded that the company's experimental treatment for metastatic renal cell carcinoma would likely fail.02/24/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 23, 2017 Category: Urology & Nephrology Source Type: news

Argos says independent committee predicts trial failure, shares slump
(Reuters) - Argos Therapeutics Inc said on Wednesday that an independent data monitoring committee concluded that the company's experimental treatment for metastatic renal cell carcinoma would likely fail. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Does Active Surveillance Benefit Patients With Metastatic RCC?
Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities. (Source: CancerNetwork)
Source: CancerNetwork - February 22, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: ASCO Genitourinary Cancers Symposium News Renal Cell Carcinoma Source Type: news

Clinical Data From Phase I Dose-Escalation Study Of NKTR-214
Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma (RCC) were presented at ASCO GU 2017.02/22/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 21, 2017 Category: Urology & Nephrology Source Type: news

Computer-Aided Evaluation of Tumor Response Could Benefit RCC Patients
Computer-assisted tumor objective response evaluations for patients with metastatic renal cell carcinoma can save time and reduce errors. (Source: CancerNetwork)
Source: CancerNetwork - February 21, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: ASCO Genitourinary Cancers Symposium News Renal Cell Carcinoma Source Type: news

Active Surveillance in Small Renal Masses
In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2017 Category: Cancer & Oncology Authors: Phillip M. Pierorazio, MD Ridwan Alam Tags: ASCO Genitourinary Cancers Symposium Renal Cell Carcinoma Source Type: news

Phase II study supports potential for Roche ’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Roche today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - February 18, 2017 Category: Pharmaceuticals Source Type: news

Phase II study supports potential for Roche ’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Roche today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 18, 2017 Category: Pharmaceuticals Source Type: news

Pathology Aids in Diagnosis of Hereditary Leiomyomatosis, RCC
Suspicious pathology from kidney tumors was significantly associated with testing positive for fumarate hydratase mutations, which may aid in the early diagnosis of hereditary leiomyomatosis and renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Long-Term RCC Control With Immunotherapy, Despite Early Discontinuation
Immunotherapy offers durable responses lasting more than 6 months after treatment discontinuation for some patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: ASCO Genitourinary Cancers Symposium News Renal Cell Carcinoma Source Type: news

Antibiotics May Damper Effect of PD-1/PD-L1 Blockade
(MedPage Today) -- Worse PFS in metastatic renal cell carcinoma (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 14, 2017 Category: Hematology Source Type: news

Genitourinary Cancers Symposium (GUCS) 2017
In a small study of patients with advanced renal cell carcinoma, nearly half had durable responses after discontinuing checkpoint inhibitors because of toxicities.02/14/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 14, 2017 Category: Urology & Nephrology Source Type: news